Leadership Team

Orasis is led by a collaborative team of expert industry executives, Optometrists and Ophthalmologists with a diverse set of experiences in ophthalmic and optometric drug development and research, finance, as well as business development.

Elad Kedar
ELAD KEDAR
Chief Executive Officer

Elad Kedar has nearly 20 years of executive experience in the pharmaceutical industry, developing and growing healthcare organizations. His experience includes holding a variety of senior positions across different geographic locations and business environments, such as CFO of Eli Lilly South-East Europe and founder of PharmaSwiss Israel. Mr. Kedar brings his leadership and expertise to all stages of the pharmaceutical life cycle, from clinical development to commercialization.

Mr. Kedar holds an MBA from INSEAD and a B.A. in accounting and law from Tel Aviv University.

PAUL SMITH
President and Chief Operating Officer

Paul Smith brings over two decades of experience as a leader in Ophthalmics with a proven track record of launching, accelerating growth and building a culture that attracts top talent. His leadership experience spans startups, big pharma and device across sales, marketing, operations and market development verticals. Mr. Smith brings extensive global ophthalmic experience leading teams, building brands and commercializing products.

Mr. Smith earned his B.A. from the University of Central Florida and an MBA from the University of Florida.

Julie Speed new
JULIE SPEED
Senior Vice President
Head of Strategy and Marketing

Julie Speed brings over two decades of proven ophthalmic leadership across both pharmaceutical and medical device. Her expertise spans from commercial leadership positions at Alcon and Johnson & Johnson Vision-Surgical, progressing commercial strategy and brands, to start-up organizations at Eyevance and TearLab, building marketing strategy and teams from the ground up. Her broad marketing and launch experience with U.S. and global brands will help accelerate Orasis towards launch readiness. 

Ms. Speed earned her B.S. in Biomedical Science from Texas A&M University and MBA from Texas Christian University.

Ron Neumann
RON NEUMANN, M.D.
Chief Medical Officer

Dr. Ron Neumann has more than 30 years of experience as an ophthalmologist and working in the pharmaceutical industry. He has held many leading roles in clinical development and marketing, such as serving as the head of ophthalmology at Teva Pharmaceutical Industries. Dr. Neumann currently works as an advisor in the field of ocular drug development. He is also the chairperson for ISOPT Clinical (The International Symposium on Ocular Pharmacology and Therapeutics).

Dr. Neumann holds an M.D. in ocular immunology from Massachusetts Eye and Ear Infirmary. He completed his fellowship program in inflammatory eye diseases at Harvard University.

Sharon Amzel-Sasson
SHARON AMZEL-SASSON
VP Pharmaceutical Development and Manufacturing

Sharon Amzel-Sasson is a development and operations executive with 15 years of experience leading drug development (CMC) and project management teams in the biomedical industry, both in large multinational corporations as well as in startup environments. Ms. Amzel-Sasson is an expert in the development and manufacturing of pharmaceutical drugs and drug-device combination products, with extensive expertise in ophthalmic and sterile products.

Ms. Amzel-Sasson holds an MBA from Tel Aviv University and a B.S. in biotechnology and food engineering from the Technion – Israel Institute of Technology.

Julia Reznick

JULIA REZNICK
VP Finance and Business Development

Julia Reznick is a finance and business development executive with more than 18 years of experience in the pharmaceutical industry. Her recent roles include senior positions at Teva Pharmaceutical Industries, where she led multinational teams in R&D, finance, and commercialization for innovative products. Ms. Reznick has a broad range of expertise in various types of business development deals and M&A activities.

Ms. Reznick holds an MBA and a B.A. in economics and business management from Tel Aviv University.

IRIS MEISNER
Head of Regulatory Affairs
Iris Meisner is a Regulatory Affairs professional with over 30 years worldwide experience in Innovative and Generics products. She occupied senior regulatory positions at known corporations such as CibaVision and Teva Pharmaceutical Industries, as well as worked with smaller pharma companies in the field of CNS, Hepatology and now Ophthalmology. Her responsibilities covered regulatory drug development and post-marketing maintenance in parallel to building and leading large international regulatory teams.

Ms. Meisner holds a Federal Diploma of Pharmacy from the University of Geneva, Switzerland.
LAURA TRUSSO
Director of US Clinical Operations

Laura Trusso is a clinical research professional with over 30 years of experience in the pharmaceutical and CRO industries.  Over the course of her career, Ms. Trusso has held leadership positions at Bausch+Lomb, ICON Clinical Research and the Center for Health and Technology at the University of Rochester Medical Center. She played a key role in the operational management of multiple clinical programs that led to 6 US FDA approved prescription products and multiple non-prescription drug products.  

Ms. Trusso holds a MS in Environmental Toxicology from the University of Rochester